Ziel
The AutArt diagnostic toolkit is a medical device that automatically diagnoses the progression of Rheumatoid Arthritis (RA)
on an X-Ray image by using the Sharp/van der Heijde scoring system.
This Phase 1 feasibility study will support the clinical validation of the device in Phase 2 that we estimate will cost between
1.5-2 million EUR; with the first market sale scheduled within 2 years, sold SAS (Software as a Service).
RA is a chronic autoimmune disease that causes inflammation of the lining of the joints, which can destroy cartilage and
bone, causing deformity of the joints. RA is a serious economic and social problem, 20-30% of early RA patients become
permanently work disabled during the first 2-3 years of the disease and more than 50% of patients with RA became work
disabled during the first ten years of the disease. Classical disease-modifying drugs are ineffective in about 10-15% of the
cases, furthermore, biologic agents may also be ineffective. Early detection, regular clinical monitoring and comparable,
objective evaluation is essential for successful treatment.
The AutArt medical device is the result of 2 years of intensive R&D and at the moment there are no serious competitors in
the market, so this is the time to act for a dynamically rising market share in the RA diagnostic market. The target group
consists of MDs, medical institutions and pharmaceutical companies. The unique selling points of the product are objectivity,
comparability and precision.
In the EU, RA treatments cost 25.1 billion EUR in 2009. With more precise diagnosis and objective follow-up this can be
decreased considerably with the AutArt medical device.
This project is in line with the 282/2014/EU regulation on the establishment of a third Programme for the Union’s action in the
field of health (2014-2020) because it contributes to the sustainability of the healthcare system and provides millions of
people with better treatment through more precise diagnosis.
Wissenschaftliches Gebiet
CORDIS klassifiziert Projekte mit EuroSciVoc, einer mehrsprachigen Taxonomie der Wissenschaftsbereiche, durch einen halbautomatischen Prozess, der auf Verfahren der Verarbeitung natürlicher Sprache beruht.
CORDIS klassifiziert Projekte mit EuroSciVoc, einer mehrsprachigen Taxonomie der Wissenschaftsbereiche, durch einen halbautomatischen Prozess, der auf Verfahren der Verarbeitung natürlicher Sprache beruht.
- natural sciencescomputer and information sciencessoftware
- medical and health sciencesclinical medicinerheumatology
- natural sciencescomputer and information sciencescomputer securitycryptography
- medical and health sciencesbasic medicineimmunologyautoimmune diseases
- medical and health sciencesbasic medicineimmunologyimmunotherapy
Programm/Programme
Thema/Themen
Aufforderung zur Vorschlagseinreichung
Andere Projekte für diesen Aufruf anzeigenUnterauftrag
H2020-SMEINST-1-2015
Finanzierungsplan
SME-1 - SME instrument phase 1Koordinator
1114 BUDAPEST
Ungarn
Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen).